Boehringer Ingelheim and the World Stroke Organization Announce Partnership in the World Stroke Academy

Ingelheim, Germany (ots/PRNewswire) -

- For Healthcare Media Outside the U.S.A., Canada, and Japan

Boehringer Ingelheim announced today that it will become the
founding sponsor of the World Stroke Academy, a novel training
initiative for stroke professionals being developed by the World
Stroke Organization (WSO). This latest educational initiative from
the WSO will bring together an international group of stroke experts
- led by Professor Michael Brainin of the Danube University Krems,
Austria - to provide information about stroke and knowledge for
health professionals and medical doctors in order to improve
prevention, therapy and management of stroke.

Professor Bo Norrving, President of the WSO said: "The World
Stroke Academy is a project of the World Stroke Organization and aims
at improving education on a global scale. It is a platform open to
all stroke societies aiming at global effectiveness of fighting
stroke and its physical and mental consequences."

Dr. Manfred Haehl, Corporate Senior Vice President Medicine,
Boehringer Ingelheim said: "Boehringer Ingelheim is committed to
patient care and we are proud to support initiatives that have
potential to benefit all patients. Stroke is one of the biggest
causes of death and severe disability worldwide, and a great many
patients simply don't have access to specialist care. We hope the
World Stroke Academy will contribute to training a new generation of
specialists who can help provide that care."

The World Health Organization estimates that 5.7 million people
in the world die each year from stroke.[1] Among survivors, 40%
experience moderate to severe disability and 10% require
institutional care.[2]

The World Stroke Academy aims to provide a mixture of online and
conventional activities to educate and help facilitate training of
stroke professionals across all regions of the world. Key objectives
of the initiative include:

- Promoting knowledge and education on stroke management on a global
level according to the WSO mission statement
- Improving and standardising educational standards in primary and
secondary stroke prevention, acute management and rehabilitation
- Leveraging guidelines to ensure best practice is implemented within all
regions of the world
- Further developing the WSO as a leading global educator.

Please be advised

This release is from Boehringer Ingelheim Corporate Headquarters
in Germany. Please be aware that there may be national differences
between countries regarding specific medical information, including
licensed uses. Please take account of this when referring to the
information provided in this document. This press release is not
intended for distribution within the U.S.A.

Notes to Editor

About the World Stroke Organization

The World Stroke Organization (WSO) was established in October
2006 from the merger of the International Stroke Society (ISS) and
the World Stroke Federation (WSF), the two lead organisations
representing stroke globally. The mission of WSO is to provide access
to stroke care and to promote research and teaching in this area that
will improve the care of stroke victims throughout the world.

For more information please visit http://www.world-stroke.org

Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading
pharmaceutical companies. Headquartered in Ingelheim, Germany, it
operates globally with 138 affiliates in 47 countries and 41,300
employees. Since it was founded in 1885, the family-owned company has
been committed to researching, developing, manufacturing and
marketing novel products of high therapeutic value for human and
veterinary medicine.

In 2008, Boehringer Ingelheim posted net sales of 11.6 billion
euro while spending one fifth of net sales in its largest business
segment Prescription Medicines on research and development.

For more information please visit
http://www.boehringer-ingelheim.com

For related media information please click here:

http://www.boehringer-ingelheim.com/corporate/news/information_pa
cks/acutestroke.asp

References

---------------------------------

[1] Cardiovascular diseases. Fact sheet No.317. February 2007.
WHO. https://www.who.int/mediacentre/factsheets/fs317/en/

[2] National Institute of Neurological Disorders and Stroke.
Stroke Rehabilitation Information.
http://www.ninds.nih.gov/disorders/stroke/stroke_rehabilitation.htm

INGELHEIM, Germany, May 27 /PRNewswire/ --

ots Originaltext: Boehringer Ingelheim
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Contact: Judith von Gordon, Corporate Division Communications,
Boehringer Ingelheim GmbH, 55216 Ingelheim/Germany, Tel: Phone
+49-61-32-77-3582, E-mail: press@boehringer-ingelheim.com